Ser1795

Site Information
VAsPRRLsNVsssGs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3558891

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 )
Disease tissue studied:	breast cancer ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , neuroblastoma ( 4 ) , ovarian cancer ( 3 )
Relevant cell line - cell type - tissue:	293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 14 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 8 ) , A498 (renal) ( 9 ) , breast ( 1 ) , BT-20 (breast cell) ( 5 ) , BT-549 (breast cell) ( 5 ) , Calu 6 (pulmonary) ( 5 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 6 ) , Flp-In T-Rex-293 (epithelial) ( 6 ) , H2009 (pulmonary) ( 5 ) , H2077 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , H322M (pulmonary) ( 5 ) , HCC366 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 5 ) , HeLa (cervical) ( 11 ) , HUES-9 ('stem, embryonic') ( 7 ) , LOU-NH91 (squamous) ( 5 ) , MCF-7 (breast cell) ( 2 ) , MDA-MB-231 (breast cell) ( 5 ) , MDA-MB-468 (breast cell) ( 5 ) , NB10 (neural crest) ( 4 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H1648 (pulmonary) ( 5 ) , NCI-H1703 (squamous) ( 12 ) , NCI-H2030 (pulmonary) ( 5 ) , NCI-H3255 (pulmonary) ( 10 , 13 ) , NCI-H460 (pulmonary) ( 5 ) , NPC (neural crest) ( 4 ) , ovary ( 3 )

Upstream Regulation
Treatments:	metformin ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
7	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
8	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
9	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
10	Possemato A (2009) CST Curation Set: 7399; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
11	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
12	Moritz A (2008) CST Curation Set: 5783; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
13	Moritz A (2008) CST Curation Set: 5780; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
14	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info